Clinical trials advance cancer research and are the only way to find safe and potentially more effective therapies to treat cancer. Patients who enroll in clinical trials have access to new treatments that may offer better results than standard treatment.
Clinical Trial Holds Promise for Patients with Advanced Breast Cancer
Hopkins scientists test ability of low doses of drugs, once deemed too toxic for humans, to 'reprogram' cancer cells and restore normal gene function.
Stephen Baylin, M.D., deputy director of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, makes it easy even for someone who's never stepped foot inside a scientific laboratory to understand how his sophisticated research on epigenetic-targeted drugs show promise at extending the life of patients with advanced breast cancer. Read more
- Johns Hopkins researchers find that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels. Read more.
- Johns Hopkins scientists report new findings about a gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients’ risk for carpal tunnel syndrome at the San Antonio Breast Cancer Symposium. Read more.
- Johns Hopkins scientists discover that SPCA2 -- a protein found in very high levels in human breast cancer cells – both pumps calcium out of cells and also moonlights as a signal to get massive quantities of the stuff to flow in, holding the promise of a new therapeutic target for certain breast cancers. Read more.
- Johns Hopkins scientists, one year after completing the first large-scale report sequencing breast and colon cancer genes, find a cancer “landscape” dominated by genes that each are mutated in relatively few cancers. The report suggests that less-commonly mutated genes can be grouped into clusters according to their pathways. Read more.
- Johns Hopkins scientists complete the first draft of the genetic code for breast and colon cancers. Their report identifies close to 200 mutated genes linked to these cancers, most of which were not previously recognized as associated with tumor initiation, growth, spread or control.
- Johns Hopkins scientists find that a method they developed to screen body fluids for certain kinds of cells and some of their genetic blueprint is twice as accurate at spotting breast cancer cells as a pathologist’s view with a microscope.Read more.